NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues rose 5 percent, and it swung from a loss to a profit.

The San Diego-based firm missed analysts' consensus estimate, and its shares plunged 21 percent to $32.99 in after-hours trade — though its shares were trading at $35.23 in early Wednesday trade. The shortfall was due to a few issues, including a quality control issue related to sequencing reagent kits that could impact Illumina's Q4 revenues as well.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.